0001209191-20-064531.txt : 20201218
0001209191-20-064531.hdr.sgml : 20201218
20201218191823
ACCESSION NUMBER: 0001209191-20-064531
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201217
FILED AS OF DATE: 20201218
DATE AS OF CHANGE: 20201218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ramasastry Saira
CENTRAL INDEX KEY: 0001547959
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 201401999
MAIL ADDRESS:
STREET 1: 501 CANAL BLVD.
CITY: RICHMOND
STATE: CA
ZIP: 94804
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-12-17
0
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001547959
Ramasastry Saira
C/O SANGAMO THERAPEAUTICS, INC.
7000 MARINA BLVD
BRISBANE
CA
94405
1
0
0
0
Common Stock
2020-12-17
4
M
0
10000
5.99
A
25000
D
Common Stock
2020-12-17
4
S
0
10000
13.2747
D
15000
D
Stock Option (Right-to-Buy)
5.99
2020-12-17
4
M
0
10000
0.00
D
2026-06-13
Common Stock
10000
0
D
Includes 10,000 shares of common stock subject to restricted stock units ("RSUs") granted on May 15, 2020. The RSUs will fully vest on the earlier of (x) May 15, 2021 (the first anniversary of the date of grant) or (y) the day prior to Issuer's 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service through such dates as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended") and subject to acceleration as defined in the 2018 EIP, as amended.
The price reported is a weighted average price. The shares were sold at prices ranging from $13.26 to $13.32 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
The option was immediately exercisable for all option shares, but shares purchased under the option were subject to certain repurchase rights by the Issuer upon the cessation of the Reporting Person's service on the Board of Directors of the Issuer. The shares subject to each option vested in monthly installments upon completion of each month of Board service over a three year period measured from the date of grant.
/s/ Matthew Colvin, Attorney-in-Fact for Saira Ramasastry
2020-12-18